A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

The recent success of cancer immunotherapies has highlighted the benefit of harnessing the
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …

A common theme across multiple successful immunotherapies for cancer is the recognition
of tumor-specific mutations (neoantigens) by T cells. The rapid discovery of such antigen …

One key barrier to improving efficacy of personalized cancer immunotherapies that are
dependent on the tumor antigenic landscape remains patient stratification. Although patients …

The accurate selection of neoantigens that bind to class I human leukocyte antigen (HLA)
and are recognized by autologous T cells is a crucial step in many cancer immunotherapy …

The accurate identification and prioritization of antigenic peptides is crucial for the
development of personalized cancer immunotherapies. Publicly available pipelines to …

Studies have characterized the immune escape landscape across primary tumors. However,
whether late-stage metastatic tumors present differences in genetic immune escape (GIE) …

Motivation Predicting the binding between T-cell receptor (TCR) and peptide presented by
human leucocyte antigen molecule is a highly challenging task and a key bottleneck in the …

Vaccine development stands as a cornerstone of public health efforts, pivotal in curbing
infectious diseases and reducing global morbidity and mortality. However, traditional …

Highlights•CVs have been characterized by positive safety and immunogenicity profiles but
low levels of clinical efficacy.•Novel CV strategies entail personalized formulations and …